What is the share price of Aarti Pharmalabs Ltd (AARTIPHARM) today?
The share price of AARTIPHARM as on 5th February 2026 is ₹783.35. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Aarti Pharmalabs Ltd (AARTIPHARM) share?
The past returns of Aarti Pharmalabs Ltd (AARTIPHARM) share are- Past 1 week: 3.63%
- Past 1 month: 5.01%
- Past 3 months: -7.25%
- Past 6 months: -9.89%
- Past 1 year: 23.11%
- Past 3 years: 201.87%
- Past 5 years: 171.76%
What are the peers or stocks similar to Aarti Pharmalabs Ltd (AARTIPHARM)?
The peers or stocks similar to Aarti Pharmalabs Ltd (AARTIPHARM) include:What is the dividend yield % of Aarti Pharmalabs Ltd (AARTIPHARM) share?
The current dividend yield of Aarti Pharmalabs Ltd (AARTIPHARM) is 0.64.What is the market cap of Aarti Pharmalabs Ltd (AARTIPHARM) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Aarti Pharmalabs Ltd (AARTIPHARM) is ₹7100.86 Cr as of 5th February 2026.What is the 52 week high and low of Aarti Pharmalabs Ltd (AARTIPHARM) share?
The 52-week high of Aarti Pharmalabs Ltd (AARTIPHARM) is ₹971 and the 52-week low is ₹574.45.What is the PE and PB ratio of Aarti Pharmalabs Ltd (AARTIPHARM) stock?
The P/E (price-to-earnings) ratio of Aarti Pharmalabs Ltd (AARTIPHARM) is 26.07. The P/B (price-to-book) ratio is 3.57.Which sector does Aarti Pharmalabs Ltd (AARTIPHARM) belong to?
Aarti Pharmalabs Ltd (AARTIPHARM) belongs to the Health Care sector & Labs & Life Sciences Services sub-sector.How to buy Aarti Pharmalabs Ltd (AARTIPHARM) shares?
You can directly buy Aarti Pharmalabs Ltd (AARTIPHARM) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Aarti Pharmalabs Ltd
AARTIPHARM Share Price
783.350.86% (+6.70)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
AARTIPHARM Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
AARTIPHARM Performance & Key Metrics
AARTIPHARM Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 29.61 | 3.57 | 0.64% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 35.40 | 5.62 | 0.61% |
AARTIPHARM Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
AARTIPHARM Company Profile
Aarti Pharmalabs Ltd manufactures active pharmaceutical ingredients and intermediates, offering CDMO services for drug development and production, with a focus on oncology and corticosteroid products.
DIVISLAB
PE Ratio
74.41
74.41
1Y Return
0.29%
0.29%
Buy Reco %
56.00
56.00
SYNGENE
PE Ratio
37.20
37.20
1Y Return
38.41%
38.41%
Buy Reco %
83.33
83.33
PE Ratio
1,017.74
1,017.74
1Y Return
13.94%
13.94%
Buy Reco %
0.00
0.00
VIMTALABS
PE Ratio
28.50
28.50
1Y Return
8.10%
8.10%
Buy Reco %
0.00
0.00
PE Ratio
59.46
59.46
1Y Return
18.71%
18.71%
Buy Reco %
0.00
0.00
AARTIPHARM Sentiment Analysis
AARTIPHARM Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
AARTIPHARM Stock Summary · November 2025
The company is currently grappling with operational challenges stemming from adjustments at its plants and the significant capital investment in the Atali project, which is expected to enhance production capacity and contribute to revenue growth in the coming years. Despite a year-over-year revenue increase of 11%, profitability has been pressured by forex losses and margin declines, particularly in the API segment, which is anticipated to normalize in the second half of the year. The Xanthine Derivatives segment remains a strong performer, accounting for over half of turnover, while the CDMO services are poised for substantial growth, supported by a robust project pipeline. Management is optimistic about future prospects, emphasizing strategic partnerships and new product launches, particularly in oncology, to drive recovery and long-term growth. However, the company remains cautious, acknowledging the need for effective inventory management and operational efficiency to navigate the competitive landscape and stabilize financial performance.
AARTIPHARM Stock Growth Drivers
AARTIPHARM Stock Growth Drivers
7Operational Capacity Expansion
Aarti Pharmalabs has successfully increased its production capacity in the Xanthine segment from 5,000 to
Sales Growth and Revenue Targets
The company is on track to achieve a year-on-year sales growth target of 30% to
AARTIPHARM Stock Challenges
AARTIPHARM Stock Challenges
6Declining Financial Performance
Aarti Pharmalabs has reported a significant decline in key financial metrics. The standalone revenue for
Margin Pressures
The company is experiencing significant pressure on its gross and EBITDA margins, which have declined
AARTIPHARM Forecast
AARTIPHARM Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
AARTIPHARM
AARTIPHARM
Income
Balance Sheet
Cash Flow
Annual Normal View
AARTIPHARM Income Statement
AARTIPHARM Income Statement
Annual Normal View
| Financial Year | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 1,202.45 | 1,947.55 | 1,857.51 | 2,125.19 | 1,911.16 | ||||||
Raw Materials | 0.00 | 686.72 | 1,295.12 | 1,040.67 | 1,063.66 | 1,464.32 | ||||||
| Power & Fuel Cost | 44.14 | 75.10 | 84.03 | 81.32 | ||||||||
| Employee Cost | 85.20 | 121.32 | 128.03 | 148.65 | ||||||||
| Selling & Administrative Expenses | 27.35 | 110.28 | 87.56 | 130.79 | ||||||||
| Operating & Other expenses | 149.58 | 1.37 | 126.28 | 226.29 | ||||||||
EBITDA | 0.00 | 209.46 | 344.36 | 390.94 | 474.48 | 446.84 | ||||||
| Depreciation/Amortization | 0.00 | 42.12 | 62.54 | 73.24 | 86.90 | 93.42 | ||||||
| PBIT | 0.00 | 167.34 | 281.82 | 317.70 | 387.58 | 353.42 | ||||||
| Interest & Other Items | 0.00 | 11.96 | 21.05 | 17.21 | 26.90 | 34.01 | ||||||
| PBT | 0.00 | 155.38 | 260.77 | 300.49 | 360.68 | 319.41 | ||||||
| Taxes & Other Items | 0.00 | 33.13 | 67.28 | 83.59 | 88.29 | 79.63 | ||||||
| Net Income | 0.00 | 122.25 | 193.49 | 216.90 | 272.39 | 239.78 | ||||||
| EPS | 0.00 | 4,890.00 | 42.58 | 23.93 | 30.06 | 26.46 | ||||||
| DPS | 0.00 | 0.00 | 2.00 | 3.00 | 5.00 | 5.00 | ||||||
| Payout ratio | 0.00 | 0.00 | 0.05 | 0.13 | 0.17 | 0.19 |
AARTIPHARM Company Updates
FY 2026FY 2026
Investor Presentation
Nov 11PDF
Sep 23PDF
Aug 13PDF
AARTIPHARM Stock Peers
AARTIPHARM Past Performance & Peer Comparison
AARTIPHARM Past Performance & Peer Comparison
Comparing 3 stocks from
Health CareLabs & Life Sciences Services
Compare valuation on Screener
Health CareLabs & Life Sciences Services
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Aarti Pharmalabs Ltd | 26.07 | 3.57 | 0.64% |
| Divi's Laboratories Ltd | 74.41 | 10.89 | 0.49% |
| Syngene International Ltd | 37.20 | 3.91 | 0.27% |
| Dishman Carbogen Amcis Ltd | 1,017.74 | 0.57 | — |
AARTIPHARM Stock Price Comparison
Compare AARTIPHARM with any stock or ETFCompare AARTIPHARM with any stock or ETF
AARTIPHARM
AARTIPHARM Holdings
AARTIPHARM Shareholdings
AARTIPHARM Promoter Holdings Trend
AARTIPHARM Promoter Holdings Trend
AARTIPHARM Institutional Holdings Trend
AARTIPHARM Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
AARTIPHARM Shareholding Pattern
AARTIPHARM Shareholding Pattern
AARTIPHARM Shareholding History
AARTIPHARM Shareholding History
Foreign Institutions
Mutual Funds Invested in AARTIPHARM
Mutual Funds Invested in AARTIPHARM
No mutual funds holding trends are available
Top 5 Mutual Funds holding Aarti Pharmalabs Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 0.4583% | Percentage of the fund’s portfolio invested in the stock 0.16% | Change in the portfolio weight of the stock over the last 3 months -0.03% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 134/206 (-2) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.1897% | Percentage of the fund’s portfolio invested in the stock 0.51% | Change in the portfolio weight of the stock over the last 3 months -0.04% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 61/255 (-28) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.1069% | Percentage of the fund’s portfolio invested in the stock 0.52% | Change in the portfolio weight of the stock over the last 3 months 0.52% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 78/84 (+2) |
Compare 3-month MF holding change on Screener
smallcases containing AARTIPHARM stock
smallcases containing AARTIPHARM stock
Looks like this stock is not in any smallcase yet.
AARTIPHARM Events
AARTIPHARM Events
AARTIPHARM Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
AARTIPHARM Dividend Trend
No dividend trend available
AARTIPHARM Upcoming Dividends
AARTIPHARM Upcoming Dividends
No upcoming dividends are available
AARTIPHARM Past Dividends
AARTIPHARM Past Dividends
Cash Dividend
Ex DateEx DateSep 15, 2025
Final
Final | Div/Share: ₹2.50
Dividend/Share
₹2.50
Ex DateEx Date
Sep 15, 2025
Cash Dividend
Ex DateEx DateFeb 14, 2025
Interim
Interim | Div/Share: ₹2.50
Dividend/Share
₹2.50
Ex DateEx Date
Feb 14, 2025
Cash Dividend
Ex DateEx DateJul 31, 2024
Final
Final | Div/Share: ₹1.00
Dividend/Share
₹1.00
Ex DateEx Date
Jul 31, 2024
Cash Dividend
Ex DateEx DateFeb 16, 2024
Interim
Interim | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
Feb 16, 2024
AARTIPHARM Stock News & Opinions
AARTIPHARM Stock News & Opinions
Articles & Videos
Corporate
Aarti Pharmalabs to table results
Aarti Pharmalabs will hold a meeting of the Board of Directors of the Company on 9 February 2026.Powered by Capital Market - Live
6 days agoCapital Market - Live
Spotlight
Aarti Pharmalabs slides after Q2 PAT tumbles 49% YoY to Rs 28 cr
Revenue from operations fell 8.66% YoY to Rs 418.33 crore in the quarter ended 30 September 2025. Profit before tax (PBT) stood at Rs 38.69 crore in Q2 FY26, down 46.09% from Rs 71.77 crore in the same period last year. Total expenses decreased 2.99% to Rs 379.05 crore in Q2 FY26, compared to Rs 379.05 crore in Q2 FY26. The cost of materials consumed stood at Rs 203.46 crore (down 4.91% YoY), employee benefit expenses were Rs 43.41 crore (up 15.05% YoY) and finance costs stood at Rs 10.67 crore (up 93.64% YoY) during the period under review. On half-year basis, the company's consolidated net profit climbed 29.64% to Rs 77.45 crore on 20.62% decrease in revenue to Rs 804.53 crore in H1 FY26 over H1 FY25. Aarti Pharmalabs (APL) is an established, internationally recognized manufacturer of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, new chemical entities (NCEs), and xanthine derivatives based in India. Powered by Capital Market - Live
2 months agoCapital Market - Live
Earnings
Aarti Pharmalabs consolidated net profit declines 48.88% in the September 2025 quarter
Net profit of Aarti Pharmalabs declined 48.88% to Rs 27.92 crore in the quarter ended September 2025 as against Rs 54.62 crore during the previous quarter ended September 2024. Sales declined 8.67% to Rs 418.33 crore in the quarter ended September 2025 as against Rs 458.03 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales418.33458.03 -9 OPM %17.7120.45 - PBDT63.4692.65 -32 PBT38.6971.77 -46 NP27.9254.62 -49 Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Aarti Pharmalabs to declare Quarterly Results
Aarti Pharmalabs will hold a meeting of the Board of Directors of the Company on 9 November 2025.Powered by Capital Market - Live
3 months agoCapital Market - Live
Spotlight
Aarti Pharmalabs gains on commissioning phase 1 of new Gujarat facility
According to an exchange filing, the company confirmed that it has received all necessary approvals and permissions to commence operations at the site. Phase 1 includes a total reactor capacity of 440 kilolitres (kL), with 63 reactors. The greenfield facility spans 80 acres and is designed for significant scalability, with potential to expand capacity up to 8'10 times that of Phase 1 in the future. Aarti Pharmalabs (APL) is an established, internationally recognized manufacturer of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, new chemical entities (NCEs), and xanthine derivatives based in India. The company reported a 10.73% decline in consolidated net profit to Rs 49.50 crore in Q1 FY26, compared to Rs 55.45 crore posted in Q1 FY25. Revenue from operations slumped 30.47% YoY to Rs 386.19 crore in the quarter ended 30 June 2025. Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Aarti Pharmalabs schedules AGM
Aarti Pharmalabs announced that the Annual General Meeting(AGM) of the company will be held on 22 September 2025.Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Aarti Pharmalabs fixes record date for final dividend
Aarti Pharmalabs has fixed 15 September 2025 as record date for payment of final dividend for the financial year 2024-25. The dividend will be paid on or before 20 October 2025.Powered by Capital Market - Live
5 months agoCapital Market - Live
Spotlight
Aarti Pharmalabs slides after Q1 PAT tumbles 11% YoY to Rs 50 cr
Revenue from operations slumped 30.47% YoY to Rs 386.19 crore in the quarter ended 30 June 2025. Profit before tax (PBT) stood at Rs 65.45 crore in Q1 FY26, down 11.16% from Rs 73.68 crore in the same period last year. Total expenses fell 33.77% to Rs 320.54 crore in Q1 FY26, compared to Rs 484.03 crore in Q1 FY25. The cost of materials consumed stood at Rs 191.42 crore (down 8.05% YoY), employee benefit expenses were Rs 41.26 crore (up 5.17% YoY), and finance costs stood at Rs 6.79 crore (up 40.57% YoY) during the period under review. EBITDA declined 1.24% YoY to Rs 95.30 crore in Q1 FY26. However, the EBITDA margin improved to 24.68% in Q1 FY26, up from 17.37% in Q1 FY25. Aarti Pharmalabs (APL) is an established, internationally recognized manufacturer of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, new chemical entities (NCEs), and xanthine derivatives based in India. Powered by Capital Market - Live
5 months agoCapital Market - Live
Earnings
Aarti Pharmalabs consolidated net profit declines 10.73% in the June 2025 quarter
Net profit of Aarti Pharmalabs declined 10.73% to Rs 49.50 crore in the quarter ended June 2025 as against Rs 55.45 crore during the previous quarter ended June 2024. Sales declined 30.48% to Rs 386.19 crore in the quarter ended June 2025 as against Rs 555.49 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales386.19555.49 -30 OPM %24.2017.36 - PBDT88.2593.84 -6 PBT65.4573.68 -11 NP49.5055.45 -11 Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Aarti Pharmalabs to convene board meeting
Aarti Pharmalabs will hold a meeting of the Board of Directors of the Company on 12 August 2025.Powered by Capital Market - Live
6 months agoCapital Market - Live
In last 6 months, promoter holding in the company has almost stayed constant
Pledged promoter holdings is insignificant